The many faces of c-MYC
UNSPECIFIED (2003) The many faces of c-MYC. ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS, 416 (2). pp. 129-136. ISSN 0003-9861Full text not available from this repository.
Official URL: http://dx.doi.org/10.1016/S0003-9861(03)00294-7
The proto-oncogene c-MYC is implicated in various physiological processes-cell growth, proliferation, loss of differentiation, and cell death (apoptosis). Oncogenic c-MYC implies constitutive or deregulated expression of c-MYC and is associated with many human cancers often with poor prognosis. Recently, c-MYC has been implicated in the loss and dysfunction of insulin-producing beta cells in diabetes. Intriguingly, this raises the possibility that c-Myc may be a key contributor to disease, not only by deregulating cell proliferation, which is well established, but also by virtue of its opposing role in engendering apoptosis. However, given the fact that human diseases at diagnosis are generally advanced and pathologically complex, it is generally difficult to attribute a specific pathogenic role to c-MYC, or indeed any given single factor, or to assess the potential of therapies targeting individual such factors. Regulatable transgenic mouse models have shed light on these issues, have influenced our thinking about cancer, and have provided encouragement for the future development of cancer therapies based on targeting individual oncogenes such as c-MYC. Although still in its infancy, encouraging results have been reported for several approaches using gene targeting to interfere with c-MYC expression or activity both in vitro and in vivo. (C) 2003 Elsevier Inc. All rights reserved.
|Item Type:||Journal Item|
|Subjects:||Q Science > QD Chemistry
Q Science > QH Natural history > QH301 Biology
|Journal or Publication Title:||ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS|
|Publisher:||ACADEMIC PRESS INC ELSEVIER SCIENCE|
|Official Date:||15 August 2003|
|Number of Pages:||8|
|Page Range:||pp. 129-136|
Actions (login required)